STOCK TITAN

Evotec SE American Depositary Shares - EVO STOCK NEWS

Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.

Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.

With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.

Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.

Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.

Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.

As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.

Rhea-AI Summary

Evotec and Almirall have formed a strategic multi-target alliance focusing on severe skin diseases including atopic dermatitis and basal cell carcinoma. This collaboration combines Evotec's advanced AI/ML-driven iR&D platform with Almirall's expertise in medical dermatology. Evotec will handle drug discovery and pre-clinical development, while Almirall will oversee clinical development and marketing. The deal includes an undisclosed upfront payment, potential milestone payments of up to €230 million per program, and royalties on net sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
Rhea-AI Summary

Evotec SE has announced the extension and expansion of its partnership with Bristol Myers Squibb in the field of targeted protein degradation, originally established in 2018. This eight-year extension aims to develop a robust pipeline of molecular glue degraders. Evotec will utilize its EVO panOmics and EVO panHunter platforms for this endeavor. The company has received an upfront payment of $200 million, with potential total deal value reaching $5 billion, including additional royalties on product sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.42%
Tags
partnership
-
Rhea-AI Summary

Evotec SE announced an 8-year extension and expansion of its strategic partnership with Bristol Myers Squibb, initially signed in 2018, to develop a pipeline of molecular glue degraders. The collaboration, leveraging Evotec's EVO panOmics and EVO panHunter platforms, includes an upfront payment of $200 million, with the potential for total deal value reaching $5 billion through performance-based payments and royalties on product sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.42%
Tags
partnership
Rhea-AI Summary

Evotec SE will announce its financial results for Q1 2022 on May 11, 2022. A conference call will follow the announcement, providing updates on performance, scheduled for 2:00 PM CEST. Participants can dial in from various countries, including the USA (+1 877 423 0830) and UK (+44 20 3009 2470). An audio webcast will also be available on the company's homepage shortly before the event. Evotec focuses on developing effective therapeutics through innovative technologies, partnering with top pharmaceutical companies and over 800 biotechnology firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
Rhea-AI Summary

Evotec SE reported a 23% increase in group revenues for the fiscal year ended December 31, 2021, reaching €618.0 million. Adjusted EBITDA rose to €107.3 million, up 1% from the previous year. The company achieved significant operational milestones, including expanded partnerships and clinical progress. It holds a robust liquidity position with €858.2 million in cash. For 2022, Evotec expects revenues between €700 - 720 million and plans to invest €70 - 80 million in unpartnered R&D to support ongoing growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.21%
Tags
-
Rhea-AI Summary

Evotec has reached a new programme designation within its collaboration with Bristol Myers Squibb (BMY), triggering a US$ 16 million payment. This programme focuses on an antisense-based approach, distinct from previous small molecule projects, and aims to address neurodegenerative diseases. Evotec could also earn royalties and up to US$ 250 million in milestones. The collaboration enhances Evotec's pipeline, which includes the clinical-stage programme EVT8683, ultimately targeting unmet medical needs in treating neurodegeneration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
Rhea-AI Summary

Evotec SE will announce its 2021 financial results on April 12, 2022. A conference call to discuss the results and provide performance updates will take place at 02:00 PM CEST (08:00 AM EDT). Participants can join through a dedicated phone line or an audio webcast, with the on-demand version available post-event on their website. Evotec's unique business model focuses on discovering and developing therapeutics across various therapeutic areas, supported by partnerships with major pharmaceutical and biotechnology firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
-
Rhea-AI Summary

Evotec has received a milestone payment of €3 million from Bayer AG due to the advancement of BAY 2395840 into Phase II clinical trials for diabetic neuropathic pain (DNP). This investigational oral antagonist targets the bradykinin receptor B1, known to influence pain perception. The Phase II trial aims to assess its safety and efficacy compared to a placebo and is expected to conclude by the end of 2022. Dr. Cord Dohrmann expressed optimism about BAY 2395840's potential to offer a new therapeutic option for DNP patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
-
Rhea-AI Summary

Evotec has launched E.MPD, a global molecular patient database, aimed at enhancing drug development through AI and machine learning technologies. The initiative is part of Evotec's strategy to increase the probability of success (PoS) in therapeutics research. The company confirmed its goals for Action Plan 2025 and announced the appointment of Dr. Matthias Evers as Chief Business Officer to lead business development. Evotec is focused on establishing itself as a leader in precision medicine, leveraging partnerships and innovative technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
none
Rhea-AI Summary

Evotec announced a collaboration with the University of Bristol to enhance its molecular patient database focusing on nephrotic syndrome. This partnership grants Evotec access to an international cohort's longitudinal clinical data and biospecimens from hundreds of patients across Asia, India, and Africa. Evotec plans to utilize its multi-omics platforms, EVO panOmics and EVO panHunter, to identify disease mechanisms and diagnostic markers, aiming for new targeted therapies. This collaboration could significantly impact treatment options for nephrotic syndrome patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none

FAQ

What is the current stock price of Evotec SE American Depositary Shares (EVO)?

The current stock price of Evotec SE American Depositary Shares (EVO) is $4.395 as of November 4, 2024.

What is the market cap of Evotec SE American Depositary Shares (EVO)?

The market cap of Evotec SE American Depositary Shares (EVO) is approximately 1.6B.

What is Evotec SE?

Evotec SE is a global drug discovery and development company headquartered in Hamburg, Germany. It provides comprehensive solutions in drug discovery and manufacturing to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations.

What are Evotec's main business segments?

Evotec's business is divided into Shared R&D, which offers drug discovery and manufacturing services, and Just-Evotec Biologics, which provides CDMO services for biologics.

Who are Evotec's partners?

Evotec collaborates with all Top 20 Pharma companies, over 800 biotech companies, academic institutions, and other healthcare stakeholders.

What recent collaborations has Evotec entered into?

Recent collaborations include partnerships with Claris Ventures to accelerate programs into the clinic and with Variant Bio to develop treatments for fibrotic diseases.

How many employees does Evotec have?

Evotec employs over 5,000 people across 18 production sites in Europe and the United States.

What are Evotec's key therapeutic areas?

Evotec focuses on central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

What financial performance did Evotec report in 2023?

Evotec reported a 4% increase in revenues, reaching €781.4 million in 2023, despite challenging economic conditions and a cyber-attack.

What are the future goals of Evotec?

Evotec aims to focus on sustainable and profitable growth, optimizing its operations and continuing to advance its mission of developing effective therapeutics.

What is Just-Evotec Biologics?

Just-Evotec Biologics is a segment of Evotec that offers contract development and manufacturing services for biologics.

What makes Evotec's platform unique?

Evotec’s multimodal platform combines innovative technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec SE American Depositary Shares

Nasdaq:EVO

EVO Rankings

EVO Stock Data

1.56B
177.55M
2.18%
0.07%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hamburg